WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 201794
Description: Rabusertib, also known as LY2603618, is a n inhibitor of the cell cycle checkpoint kinase 2 (chk2) with potential chemopotentiating activity. Rabusertib binds to and inhibits the activity of chk2, which may prevent the repair of DNA caused by DNA-damaging agents, thus potentiating the antitumor efficacies of various chemotherapeutic agents. Chk2, an ATP-dependent serine-threonine kinase, is a key component in the DNA replication-monitoring checkpoint system and is activated by double-stranded breaks (DSBs); activated chk2 is overexpressed by a variety of cancer cell types.
MedKoo Cat#: 201794
Name: Rabusertib (LY2603618)
Chemical Formula: C18H22BrN5O3
Exact Mass: 435.0906
Molecular Weight: 436.3
Elemental Analysis: C, 49.55; H, 5.08; Br, 18.31; N, 16.05; O, 11.00
Synonym: LY2603618; LY 2603618; LY-2603618; Rabusertib
IUPAC/Chemical Name: (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea.
SMILES Code: CC1=C(Br)C=C(C(OC[C@@H]2CNCCO2)=C1)NC(NC3=NC=C(N=C3)C)=O
1. Compositions of Chk1 kinase inhibitor for cancer treatment By Colvin, Anita A.; Koppenol, Sandy; Wisdom, Wendy A. From PCT Int. Appl. (2008), WO 2008067027 A2 20080605.